Elevation Wealth Partners
RPRX icon

Elevation Wealth Partners’s Royalty Pharma RPRX Stock Holding History

Elevation Wealth Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$29.4K Buy
504
+18
+4% +$1.06K 0.01% 550
2026
Q2 		$27.3K Hold
486
– – 0.01% 487
2026
Q1 		$23.3K Hold
486
– – 0.01% 350
2025
Q4 		$18.8K Buy
486
+422
+659% +$16.1K 0.01% 386
2025
Q3 		$2.26K Buy
+64
New +$2.32K ﹤0.01% 621

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Elevation Wealth Partners's RPRX Position: Q3 2026 in Review

Elevation Wealth Partners increased its Royalty Pharma (RPRX) stake by 3.7% in Q3 2026, buying an estimated $1.06K and bringing the position to 504 shares worth $29.4K. The position accounts for 0.01% of the portfolio, ranked #550.

Elevation Wealth Partners first reported a position in RPRX in Q3 2025 and has held it in 5 quarters since. 270 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Elevation Wealth Partners held 504 shares of Royalty Pharma worth $29.4K as of Q3 2026.
  • Elevation Wealth Partners bought 18 Royalty Pharma shares in Q3 2026, an estimated $1.06K.
  • Royalty Pharma made up 0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #550 holding.
  • Elevation Wealth Partners first reported a position in Royalty Pharma in Q3 2025 and has held it in 5 quarters since.
  • 270 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.